Literature DB >> 22001118

Dual mode of glucagon receptor internalization: role of PKCα, GRKs and β-arrestins.

Lada Krilov1, Amy Nguyen, Teruo Miyazaki, Cecilia G Unson, Russell Williams, Norman H Lee, Susan Ceryak, Bernard Bouscarel.   

Abstract

Glucagon levels are elevated in diabetes and some liver diseases. Increased glucagon secretion leads to abnormal stimulation of glucagon receptors (GRs) and consequent elevated glucose production in the liver. Blocking glucagon receptor signaling has been proposed as a potential treatment option for diabetes and other conditions associated with hyperglycemia. Elucidating mechanisms of GR desensitization and downregulation may help identify new drug targets besides GR itself. The present study explores the mechanisms of GR internalization and the role of PKCα, GPCR kinases (GRKs) and β-arrestins therein. We have reported previously that PKCα mediates GR phosphorylation and desensitization. While the PKC agonist, PMA, did not affect GR internalization when tested alone, it increased glucagon-mediated GR internalization by 25-40% in GR-expressing HEK-293 cells (HEK-GR cells). In both primary hepatocytes and HEK-GR cells, glucagon treatment recruited PKCα to the plasma membrane where it colocalized with GR. We also observed that overexpression of GRK2, GRK3, or GRK5 enhanced GR internalization. In addition, we found that GR utilizes both clathrin- and caveolin-mediated endocytosis in HEK-GR cells. Glucagon triggered translocation of both β-arrestin1 and β-arrestin2 from the cytosol to the perimembrane region, and overexpression of β-arrestin1 and β-arrestin2 increased GR internalization. Furthermore, both β-arrestin1 and β-arrestin2 colocalized with GR and with Cav-1, suggesting the possible involvement of these arrestins in GR internalization.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22001118      PMCID: PMC3228254          DOI: 10.1016/j.yexcr.2011.10.001

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  47 in total

1.  The long and the short cycle. Alternative intracellular routes for trafficking of G-protein-coupled receptors.

Authors:  G Innamorati; C Le Gouill; M Balamotis; M Birnbaumer
Journal:  J Biol Chem       Date:  2001-01-09       Impact factor: 5.157

Review 2.  Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling.

Authors:  S S Ferguson
Journal:  Pharmacol Rev       Date:  2001-03       Impact factor: 25.468

3.  Regulation of membrane targeting of the G protein-coupled receptor kinase 2 by protein kinase A and its anchoring protein AKAP79.

Authors:  M Cong; S J Perry; F T Lin; I D Fraser; L A Hu; W Chen; J A Pitcher; J D Scott; R J Lefkowitz
Journal:  J Biol Chem       Date:  2001-01-22       Impact factor: 5.157

4.  Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus.

Authors:  P Shah; A Vella; A Basu; R Basu; W F Schwenk; R A Rizza
Journal:  J Clin Endocrinol Metab       Date:  2000-11       Impact factor: 5.958

5.  Protein kinase C activation stimulates the phosphorylation and internalization of the sst2A somatostatin receptor.

Authors:  R W Hipkin; Y Wang; A Schonbrunn
Journal:  J Biol Chem       Date:  2000-02-25       Impact factor: 5.157

Review 6.  Pharmacological approaches to inhibit endogenous glucose production as a means of anti-diabetic therapy.

Authors:  J G McCormack; N Westergaard; M Kristiansen; C L Brand; J Lau
Journal:  Curr Pharm Des       Date:  2001-09       Impact factor: 3.116

7.  Differential targeting of beta -adrenergic receptor subtypes and adenylyl cyclase to cardiomyocyte caveolae. A mechanism to functionally regulate the cAMP signaling pathway.

Authors:  V O Rybin; X Xu; M P Lisanti; S F Steinberg
Journal:  J Biol Chem       Date:  2000-12-29       Impact factor: 5.157

8.  Disability in patients with chronic patellofemoral pain syndrome: a randomised controlled trial of VMO selective training versus general quadriceps strengthening.

Authors:  G Syme; P Rowe; D Martin; G Daly
Journal:  Man Ther       Date:  2008-04-24

9.  beta-Arrestin 1 and 2 differentially regulate heptahelical receptor signaling and trafficking.

Authors:  T A Kohout; F S Lin; S J Perry; D A Conner; R J Lefkowitz
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-06       Impact factor: 11.205

10.  Protein kinase C(alpha) actively downregulates through caveolae-dependent traffic to an endosomal compartment.

Authors:  C Prevostel; V Alice; D Joubert; P J Parker
Journal:  J Cell Sci       Date:  2000-07       Impact factor: 5.285

View more
  16 in total

1.  Association between genetic variants and characteristic symptoms of type 2 diabetes: A matched case-control study.

Authors:  Hao-Ying Dou; Yuan-Yuan Wang; Nan Yang; Ming-Li Heng; Xuan Zhou; Huai-En Bu; Fang Xu; Tie-Niu Zhao; He Huang; Hong-Wu Wang
Journal:  Chin J Integr Med       Date:  2016-02-26       Impact factor: 1.978

2.  Genetic Determinants of Type 2 Diabetes in Asians.

Authors:  Q Qi; X Wang; G Strizich; T Wang
Journal:  Int J Diabetol Vasc Dis Res       Date:  2015-03-12

3.  Functional consequences of glucagon-like peptide-1 receptor cross-talk and trafficking.

Authors:  Sarah Noerklit Roed; Anne Cathrine Nøhr; Pernille Wismann; Helle Iversen; Hans Bräuner-Osborne; Sanne Moeller Knudsen; Maria Waldhoer
Journal:  J Biol Chem       Date:  2014-12-01       Impact factor: 5.157

4.  Autophagy mediates hepatic GRK2 degradation to facilitate glucagon-induced metabolic adaptation to fasting.

Authors:  Marta Cruces-Sande; Alba C Arcones; Rocío Vila-Bedmar; Almudena Val-Blasco; Kfir Sharabi; Daniel Díaz-Rodríguez; Pere Puigserver; Federico Mayor; Cristina Murga
Journal:  FASEB J       Date:  2019-11-22       Impact factor: 5.191

Review 5.  Endosomal trafficking in metabolic homeostasis and diseases.

Authors:  Jerome Gilleron; Anja Zeigerer
Journal:  Nat Rev Endocrinol       Date:  2022-10-10       Impact factor: 47.564

6.  Dual role of GRK5 in cancer development and progression.

Authors:  J Gambardella; A Franco; C Del Giudice; A Fiordelisi; E Cipolletta; M Ciccarelli; B Trimarco; G Iaccarino; D Sorriento
Journal:  Transl Med UniSa       Date:  2016-05-16

7.  Identification and characterization of amlexanox as a G protein-coupled receptor kinase 5 inhibitor.

Authors:  Kristoff T Homan; Emily Wu; Alessandro Cannavo; Walter J Koch; John J G Tesmer
Journal:  Molecules       Date:  2014-10-22       Impact factor: 4.411

8.  RAMP2 Influences Glucagon Receptor Pharmacology via Trafficking and Signaling.

Authors:  Jaimini Cegla; Ben J Jones; James V Gardiner; David J Hodson; Thomas Marjot; Emma R McGlone; Tricia M Tan; Stephen R Bloom
Journal:  Endocrinology       Date:  2017-08-01       Impact factor: 4.736

9.  GRK5 functions as an oncogenic factor in non-small-cell lung cancer.

Authors:  Li-Ping Jiang; Song-Qing Fan; Qiu-Xia Xiong; Yong-Chun Zhou; Zuo-Zhang Yang; Gao-Feng Li; Yun-Chao Huang; Meng-Ge Wu; Qiu-Shuo Shen; Kun Liu; Cui-Ping Yang; Yong-Bin Chen
Journal:  Cell Death Dis       Date:  2018-02-20       Impact factor: 8.469

10.  A genome-wide association study identifies GRK5 and RASGRP1 as type 2 diabetes loci in Chinese Hans.

Authors:  Huaixing Li; Wei Gan; Ling Lu; Xiao Dong; Xueyao Han; Cheng Hu; Zhen Yang; Liang Sun; Wei Bao; Pengtao Li; Meian He; Liangdan Sun; Yiqin Wang; Jingwen Zhu; Qianqian Ning; Yong Tang; Rong Zhang; Jie Wen; Di Wang; Xilin Zhu; Kunquan Guo; Xianbo Zuo; Xiaohui Guo; Handong Yang; Xianghai Zhou; Xuejun Zhang; Lu Qi; Ruth J F Loos; Frank B Hu; Tangchun Wu; Ying Liu; Liegang Liu; Ze Yang; Renming Hu; Weiping Jia; Linong Ji; Yixue Li; Xu Lin
Journal:  Diabetes       Date:  2012-09-06       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.